Synaptogenix, Inc.
NASDAQ Capital MarketTotal Valuation
Synaptogenix, Inc. carries a market capitalization of 10.91M, placing it among publicly traded companies globally.
| Market Cap | 10.91M |
| Enterprise Value | N/A |
Share Statistics
Synaptogenix, Inc. currently has 2.33M shares outstanding.
| Shares Outstanding | 2.33M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 2,820.68, and the price-to-book ratio stands at -0.17.
| PE Ratio | N/A |
| PS Ratio | 2,820.68 |
| PB Ratio | -0.17 |
| P/TBV Ratio | 0.65 |
| P/FCF Ratio | -2.26 |
| P/OCF Ratio | -2.26 |
Financial Position
Synaptogenix, Inc. maintains a current ratio of 20.51, meaning it holds 20.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 20.51 |
| Quick Ratio | 14.90 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -117.98 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Synaptogenix, Inc.'s stock has gained approximately 96.74185% over the past 52 weeks. The 50-day moving average sits at 3.64, while the 200-day moving average is 3.08.
| Beta (5Y) | N/A |
| 52-Week Price Change | 96.74185% |
| 50-Day Moving Average | 3.64 |
| 200-Day Moving Average | 3.08 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Synaptogenix, Inc. generated 3,962.00 in revenue and converted that into -28.42M in net income, yielding earnings per share of -19.96. EBITDA reached -6.94M, while operating income came in at -6.94M.
| Revenue | 3,962.00 |
| Gross Profit | N/A |
| Operating Income | -6.94M |
| Pretax Income | -28.42M |
| Net Income | -28.42M |
| EBITDA | -6.94M |
| EBIT | -6.94M |
| Earnings Per Share (EPS) | -19.96 |
Balance Sheet
Total book value stands at -64.50M, with working capital of 18.82M providing operational flexibility.
| Cash & Cash Equivalents | 14.37M |
| Total Debt | N/A |
| Net Debt | -14.37M |
| Equity (Book Value) | -64.50M |
| Book Value Per Share | -45.31 |
| Working Capital | 18.82M |
Cash Flow
Synaptogenix, Inc. produced -4.95M in operating cash flow over the past twelve months.
| Operating Cash Flow | -4.95M |
| Capital Expenditures | N/A |
| Free Cash Flow | -4.95M |
| FCF Per Share | -3.48 |
Margins
Synaptogenix, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -175,250.48 and net profit margin of -717,300.61 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -175,250.48 |
| Pretax Margin | -717,300.61 |
| Profit Margin | -717,300.61 |
| EBITDA Margin | -175,127.44 |
Dividends & Yields
The company's payout ratio of -1.85 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.81 |
| Dividend Yield | N/A |
| Payout Ratio | -1.85 |
| Shareholder Yield | 10.36 |
| FCF Yield | -44.28 |
Stock Splits
Synaptogenix, Inc.'s most recent stock split took place on April 5, 2024 with a 25:1 split ratio.
| Last Split Date | 4/5/2024 |
| Split Ratio | 25:1 |
Scores
Synaptogenix, Inc. posts an Altman Z-Score of -0.91, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.91 |